A randomized evaluation of vinorelbine versus gemcitabine chemotherapy mobilization of stem cells in myeloma patients

Barbara Jeker(University of Bern), Thomas Pabst(University Hospital of Bern), Beatrice U. Mueller, Axel Ruefer(Luzerner Kantonsspital), Ulrike Bacher(Hattiesburg Clinic), Urban Novak(University of Bern), Jean-Marc Luethi(University Hospital of Bern), Behrouz Mansouri Taleghani(University of Bern), Qiyu Li(Army Medical University), Daniel Betticher, Sarah Farag(University of Bern), Simone Farese(Solothurner Spitäler)
Bone Marrow Transplantation
March 25, 2020
10.1038/s41409-020-0875-8
Cited by 10

Related Papers

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2019|3.4k
Prognostic relevance of FLT3-TKD mutations in AML: the combination matters—an analysis of 3082 patients
|Blood|2007|410
Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial
|The Lancet|2015|392
Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer (NSCLC)
|Journal of Clinical Oncology|2004|300
Prognostic significance of CCND1 (cyclin D1) overexpression in primary resected non-small-cell lung cancer
|British Journal of Cancer|1996|220